CN103705503A - Applications of Artoxanthochromane in medicines treating breast cancer - Google Patents
Applications of Artoxanthochromane in medicines treating breast cancer Download PDFInfo
- Publication number
- CN103705503A CN103705503A CN201310643927.2A CN201310643927A CN103705503A CN 103705503 A CN103705503 A CN 103705503A CN 201310643927 A CN201310643927 A CN 201310643927A CN 103705503 A CN103705503 A CN 103705503A
- Authority
- CN
- China
- Prior art keywords
- artoxanthochromane
- breast cancer
- medicines
- applications
- mcf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses applications of Artoxanthochromane in preparation of medicines treating breast cancer, and belongs to the technical field of new applications of medicines. In vitro MTT antitumor activity evaluation shows that Artoxanthochromane has obvious inhibiting effects on growth of human breast cancer cell strains 4T1, MCF-7, MDA-MB-231 and MCF-7B, so Artoxanthochromane can be used for preparing anti-breast-cancer medicines, and has good development and application prospects. The applications of Artoxanthochromane in preparation of medicines treating breast cancer are disclosed for the first time, and Artoxanthochromane has strong inhibition activity to breast cancer cells, and has substantial progress.
Description
Technical field
The present invention relates to the new purposes of compd A rtoxanthochromane, relate in particular to the application of Artoxanthochromane in preparation treatment breast cancer medicines.
Background technology
Cancer is to one of disease of human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compd A rtoxanthochromane the present invention relates to is one and within 2013, delivers (Horng-Huey Ko, et al., A Novel MonoterpeneStilbene Adduct with a4, 4-Dimethyl-2, 3-diphenylchromane Skeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): noval chemical compound 1269-1275.), this compound has brand-new framework types, this compound can be removed oxygen-derived free radicals (Horng-Huey Ko, et al., A Novel MonoterpeneStilbene Adduct with a4, 4-Dimethyl-2, 3-diphenylchromane Skeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): 1269-1275.), the purposes of the Artoxanthochromane the present invention relates in preparation treatment breast cancer medicines belongs to open first.
Summary of the invention
The object of the invention is to, according to not finding that it has the present situation of the report of anti-breast cancer activity in existing Artoxanthochromane research, provides the application of Artoxanthochromane in preparing anti-breast cancer medicines.
Described compd A rtoxanthochromane structure is as shown in formula I:
Formula I
The present invention finds by the evaluation of external MTT anti-tumor activity, Artoxanthochromane also has significant inhibitory action to the growth of human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B, and the IC50 value that suppresses this 4 strain Growth of Cells is respectively 0.69 ± 0.24 μ M, 0.77 ± 0.41 μ M, 0.68 ± 0.36 μ M and 0.72 ± 0.36 μ M.Therefore, Artoxanthochromane can, for the preparation of anti-breast cancer medicines, have good development prospect.
Purposes for the Artoxanthochromane the present invention relates in preparation treatment breast cancer medicines belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for breast cancer cell is active strong, possess outstanding substantive distinguishing features, the control for breast carcinoma simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The preparation method of compd A rtoxanthochromane involved in the present invention is referring to document (Horng-Huey Ko, et al., A Novel MonoterpeneStilbene Adduct with a4,4-Dimethyl-2,3-diphenylchromane Skeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): 1269-1275.), prepare according to the method described above compd A rtoxanthochromane.
Embodiment 1: the preparation of compd A rtoxanthochromane tablet involved in the present invention:
Get 5 and digest compound Artoxanthochromane and add 195 grams, dextrin, mix, conventional tabletting is made 1000.
Embodiment 2: the preparation of compd A rtoxanthochromane capsule involved in the present invention:
Get 5 and digest compound Artoxanthochromane and add 195 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example 1: adopt the growth inhibited effect of mtt assay assessing compound Artoxanthochromane to human breast cancer cell strain
1. method: the cell in growth logarithmic (log) phase: human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4concentration kind is in 96 orifice plates.After cell culture 24h is adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Artoxanthochromane of 0.01 μ M and 0.001 μ M.Cultivate after 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10min is placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD drug treating/Δ OD blank * 100.
2. result: Artoxanthochromane has significant inhibitory action to the growth of human breast cancer cell strain P4T1, MCF-7, MDA-MB-231 and MCF-7B.The IC50 value that this compound suppresses human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B growth is respectively 0.69 ± 0.24 μ M, 0.77 ± 0.41 μ M, 0.68 ± 0.36 μ M and 0.72 ± 0.36 μ M.
By above-described embodiment, shown, Artoxanthochromane of the present invention has good inhibitory action to the growth of human breast cancer cell strain 4T1, MCF-7, MDA-MB-231 and MCF-7B.Prove thus, Artoxanthochromane of the present invention has anti-breast cancer activity, can be for the preparation of anti-breast cancer medicines.
Claims (1)
- The application of 1.Artoxanthochromane in treatment breast cancer medicines, described compd A rtoxanthochromane structure is as shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310643927.2A CN103705503A (en) | 2013-12-04 | 2013-12-04 | Applications of Artoxanthochromane in medicines treating breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310643927.2A CN103705503A (en) | 2013-12-04 | 2013-12-04 | Applications of Artoxanthochromane in medicines treating breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103705503A true CN103705503A (en) | 2014-04-09 |
Family
ID=50399095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310643927.2A Pending CN103705503A (en) | 2013-12-04 | 2013-12-04 | Applications of Artoxanthochromane in medicines treating breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103705503A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9701655B2 (en) | 2014-02-07 | 2017-07-11 | Novogen Limited | Functionalised benzopyran compounds and use thereof |
-
2013
- 2013-12-04 CN CN201310643927.2A patent/CN103705503A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| HORNG-HUEY KO ET AL: "A Novel Monoterpene-Stilbene Adduct with a 4,4-Dimethyl-2,3-diphenylchromane Skeleton from Artocarpus xanthocarpus", 《CHEMISTRY&BIODIVERISITY》 * |
| 朱珍道等: "乳腺癌患者自由基、IL-2系统、T细胞亚群的变化及其相互关系", 《华中医学杂志》 * |
| 程晓莉等: "乳腺癌与其他一些疾病血清脂质过氧化物的探讨", 《实用医学杂志》 * |
| 项建梅等: "自由基损伤对乳腺癌患者抗氧化能力影响", 《天津医科大学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9701655B2 (en) | 2014-02-07 | 2017-07-11 | Novogen Limited | Functionalised benzopyran compounds and use thereof |
| US10370349B2 (en) | 2014-02-07 | 2019-08-06 | Kazia Therapeutics Limited | Functionalised benzopyran compounds and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103705503A (en) | Applications of Artoxanthochromane in medicines treating breast cancer | |
| CN103251605A (en) | Application of Myriberine A in preparing medicine for treating breast cancer | |
| CN103638008B (en) | The application of Artoxanthochromane in treatment skin carcinoma medicine | |
| CN103585145A (en) | Application of Artoxanthochromane in preparation of prostate cancer treatment drugs | |
| CN103536598B (en) | A kind of compound is preparing the application in Hepatoma therapy medicine | |
| CN102872086B (en) | The application of Houttuynoid A in treatment skin carcinoma medicine | |
| CN103690525A (en) | Application of Artoxanthochromane in preparation of medicine for treating tongue cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN103463049B (en) | The application of Lycojaponicumin B in preparation treatment breast cancer medicines | |
| CN103479630B (en) | The application of Lycojaponicumin A in preparation treatment breast cancer medicines | |
| CN103462969B (en) | The application of Incarviatone A in preparation treatment breast cancer medicines | |
| CN103463070B (en) | The application of Lycojaponicumin C in preparation treatment breast cancer medicines | |
| CN103463053B (en) | Lycojaponicumin A is preparing the application in Hepatoma therapy medicine | |
| CN103446150B (en) | Lycojaponicumin C is preparing the application in Hepatoma therapy medicine | |
| CN103405447B (en) | The application of Chukrasone A in preparation treatment medicine for nasopharyngeal | |
| CN102872110B (en) | Application of Houttuynoid D in medicament for treating breast cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN103462959B (en) | Incarviatone A is preparing the application in Hepatoma therapy medicine | |
| CN103446122B (en) | The application of Lycojaponicumin B in preparation treatment carcinoma of prostate medicine | |
| CN103446130B (en) | Lycojaponicumin B is preparing the application in Hepatoma therapy medicine | |
| CN103405458B (en) | Chukrasone A is preparing the application in Hepatoma therapy medicine | |
| CN103463061B (en) | The application of Lycojaponicumin C in preparation treatment carcinoma of prostate medicine | |
| CN103585144A (en) | Application of Artoxanthochromane in medicines for treating bladder cancer | |
| CN102872103B (en) | The application of Houttuynoid E in treatment medicine for nasopharyngeal | |
| CN102872141B (en) | Application of Houttuynoid E in drug for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140409 |